Patents by Inventor Kennett Sprogoe

Kennett Sprogoe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Carrier-Linked Treprostinil Prodrugs
    Publication number: 20190105400
    Abstract: The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: January 27, 2017
    Publication date: April 11, 2019
    Applicant: Ascendis Pharma A/S
    Inventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogoe, Thomas Wegge, Oliver Keil, Joachim Zettler
  • PEGylated Recombinant Human Growth Hormone Compounds
    Patent number: 10098930
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: October 16, 2018
    Assignee: Ascendis Pharma Endocrinology Division A/S
    Inventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
  • PEGylated Recombinant Human Growth Hormone Compounds
    Publication number: 20160206702
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Application
    Filed: January 19, 2016
    Publication date: July 21, 2016
    Applicant: Ascendis Pharma Growth Disorders Division A/S
    Inventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
  • PEGylated recombinant human growth hormone compounds
    Patent number: 9272048
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: March 1, 2016
    Assignee: Ascendis Pharma Growth Disorders Division A/S
    Inventors: Harald Rau, Susanne Kinderman, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
  • Long acting insulin composition
    Patent number: 9265723
    Abstract: The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: February 23, 2016
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Kennett Sprogoe, Felix Cleemann, Ulrich Hersel, Silvia Kaden-Vagt, Torben Lessmann, Harald Rau, Thomas Wegge
  • LONG ACTING INSULIN COMPOSITION
    Publication number: 20120183616
    Abstract: The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition.
    Type: Application
    Filed: July 30, 2010
    Publication date: July 19, 2012
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Kennett Sprogoe, Felix Cleemann, Ulrich Hersel, Silvia Kaden-Vagt, Torben Lessmann, Harald Rau, Thomas Wegge
  • PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS
    Publication number: 20110112021
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Application
    Filed: April 29, 2009
    Publication date: May 12, 2011
    Applicant: Ascendis Pharma AS
    Inventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe